✨ Your Portfolio is fetched and updated from zerodha.
Large Pharmaceuticals

Mankind Pharma Ltd.

MANKIND

Get real time AI alerts about this company on your WhatsApp!
Market Cap
₹1,05,753 Cr.
P/E
55.87

Mankind Pharma Ltd.

  • Mankind Pharma
  • Dr. Reddy's Lab
  • Zydus Lifesciences
FAQs on Mankind Pharma Ltd. Shareprice

Mankind Pharma has given better returns compared to its competitors.
Mankind Pharma has grown at ~21.45% over the last 2yrs while peers have grown at a median rate of 18.1%

Mankind Pharma is expensive when considering the PE ratio, however latest EV/EBIDTA is < 3 yr avg EV/EBIDTA.
Latest PE of Mankind Pharma is 55.87, while 3 year average PE is 51.72.
Also latest EV/EBITDA of Mankind Pharma is 35.36 while 3yr average is 36.51.

View FAQ's On Business
Growth Table
  • Mankind Pharma Ltd.
  • Dr. Reddy's Lab
  • Zydus Lifesciences
Balance Sheet
  • Mankind Pharma Ltd.
  • Dr. Reddy's Lab
  • Zydus Lifesciences
Balance Sheet Snapshot
No data available.
Fund Flow Analysis
  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
*Data is as of latest FY end
Profit & Loss
  • Mankind Pharma Ltd.
  • Dr. Reddy's Lab
  • Zydus Lifesciences
Cash Flow
  • Mankind Pharma Ltd.
  • Dr. Reddy's Lab
  • Zydus Lifesciences
Cash Flow Analysis
  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
Ratios
= Dominant Factor
  • Mankind Pharma Ltd.
  • Dr. Reddy's Lab
  • Zydus Lifesciences
Quarterly Results
  • Mankind Pharma Ltd.
  • Dr. Reddy's Lab
  • Zydus Lifesciences
Reverse DCF
locked
Cr
locked
5 YEAR
locked 5
10 YEAR
locked 10
20 YEAR
locked 20
Implied Growth Rate over a 5 year period*
Implied Growth Rate over a 10 year period*
Implied Growth Rate over a 20 year period*
*Implied Growth calculated using Newton-Raphson method.
Learn how to use Reverse DCF
FAQs on Mankind Pharma Ltd. Financials

Balance sheet of Mankind Pharma is strong.
But short term working capital might become an issue for this company.

Yes, The net debt of Mankind Pharma is increasing.
Latest net debt of Mankind Pharma is ₹7,192 Crs as of Mar-25.
This is greater than Mar-24 when it was -₹1,219.42 Crs.

The profit is oscillating.
The profit of Mankind Pharma is ₹1,901 Crs for TTM, ₹1,991 Crs for Mar 2025 and ₹1,913 Crs for Mar 2024.

The company seems to be paying a very low dividend.
Investors need to see where the company is allocating its profits.
Mankind Pharma latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%

Companies resources are allocated to majorly productive assets like Plant & Machinery

View FAQ's On Shareholding
Ideas Dashboard
Timeline
Watchlist
Portfolio
Alerts
Research
Stock Screener
Market
Raw Material
Data feed provided by Accord Fintech